
Access to Medicines and Health Products (MHP) Division

Member State Information Session

Update of the Road map for access to health products

09 October 2024

Access Road Map

- May 2018 decision WHA71(8), requested the DG to elaborate a road map report, outlining WHO's work on access to medicines and vaccines for 2019–2023, including activities, actions and deliverables.
- A report was drafted and revised based on consultations with Member States and other stakeholders and submitted to the seventy-second World Health Assembly (A72/17).
- The Roadmap presents a comprehensive outline of the work of WHO
- Update to reflect:
 - WHO transformation
 - GPW14
 - Lessons learnt including from COVID-19 pandemic
 - Changes in the global health outlook
 - Emergency preparedness, response and resilience
 - New mandates





MHP Key Challenges: 2024-2025

Institutionalize programmes

Institutionalize initiatives & programmes beyond COVID-19

- *C-TAP to H-TAP*
- *mRNA TT programme*
- *Biomanufacturing training*

Empower Regional & Country offices to facilitate timely support to Member States

Coordinate Internal & external partners to advance with cross-cutting work

e.g. Alignment of WHO guidelines and PQ procedures has improved timely access

Accelerate outputs

Accelerate outputs by integrating lessons learned from COVID-19

Adapt PQ & EUL processes for medicines, diagnostics, vaccines & other health products

Ensure equitable and timely access to novel health products

Visualize outcomes & impact

Increase visibility of outcomes & impact to increase accountability and trust & to showcase values

Proactive communication with media and stakeholders

Gap analysis to visualize country needs

Develop measurable indicators and consolidate a result framework

Monitor indicators for country support to evaluate effectiveness

No country in the world can address these challenges alone



\$30.5 billion

Global estimated spend on substandard and falsified medicines in LMICs¹



2.5 billion

2.5 billion people globally need one or more assistive products²



2 billion people


Experiencing financial hardship due to out-of-pocket health spending³ a majority of which includes cost of health products

¹ <https://www.who.int/publications/i/item/WHO-MVP-EMP-SAV-2019.04>

² <https://www.who.int/news-room/fact-sheets/detail/assistive-technology>

³ [https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-\(uhc\)](https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc))

Scope



WHO systematic approach for Accelerating Access

Impactful use

- Health-care Infrastructure
- Sustained capacity for healthcare workers
- Workflow integration
- Implementation research & update
- Digital Health and Innovation

Selection, procurement & supply

- Technical specifications
- Standardized Nomenclature
- Market shaping

National Policy for health products

- Guidance for essential and priority lists, Health Technology Assessment, sustained financial coverage
- Integrate global guidelines and evidence into national policy

Science, R&D & Innovation

- Convene and catalyze science
- Facilitate multi-centre trials
- Horizon scanning future innovation
- Sharing of pathogens, samples and access to products

Management of IP & Market access


- Technology and knowledge transfer
- Design target product profiles
- Licensing
- Accelerated equitable access schemes

Manufacturing

- Sustained high quality manufacturing
- Training and quality assurance
- Regional production


Global policy & regulation

- Guidelines & normative functions
- Strengthening Regulatory Capacity
- Reliance:
 - WHO Listed Authorities
 - Pre-Qualification




Health product and technology ecosystem


The parallel achievement of **affordability, availability and accessibility, acceptability and assured quality** is required for access for all populations in need.



WHO's role in supporting Member States to improve access to safe, effective and quality assured health products



Access to health products within the GPW14



Access to health products in the WHO Road Map 2025-2030 (draft):


Main strategic objectives proposed to achieve GPW14 outcomes and impact:

Ensure **safe, effective and quality-assured** health products


Improve **equitable access** to health products

Access to health products in the WHO Road Map 2025-2030 (draft):

Main programmatic areas proposed to achieve GPW14 outcomes and impact:



Timeline and next steps



Comments? Questions?

**Written comments can be submitted using online survey form
till 23 October 2024**

- <https://extranet.who.int/dataformv3/index.php/218771?lang=en>

Send any questions to roadmapaccess@who.int